Cell and Gene Therapy Market Size, Share & Trends Analysis Report By Therapy Type (Cell Therapy, Gene Therapy), By Application (Oncology, Dermatology, Musculoskeletal, Others), By Manufacturer (Biopharmaceutical and Biotechnology Companies, Pharmaceutical Companies, CDMOs/CMOs, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Emerging Trends in Cell and Gene Therapy Market

The increasing shift from oncology-centric genetically modified therapies toward non-genetically modified cell therapies acts as a key trend reshaping the cell and gene therapy market. Traditionally dominated by oncology applications, the clinical pipeline is now expanding toward non-oncology indications such as autoimmune and chronic diseases. According to the American Society of Gene & Cell Therapy, there has been a notable rise in non-genetically modified cell therapy trials targeting non-oncology indications. This transition enables manufacturers to address broader patient populations and unmet clinical needs beyond cancer, improving therapeutic accessibility and diversifying revenue streams. As a result, the market is witnessing a more balanced and indication-diverse development landscape.

Source: American Society of Gene + Cell Therapy and Straits Analysis

The expanding revenue momentum of next-generation therapies acts as a major trend driving commercialization in the market. The industry is transitioning from reliance on a few blockbuster therapies such as Yescarta and Zolgensma to a diversified portfolio of high-growth therapies, including Elevidys, Carvykti, and Breyanzi, which recorded triple-digit year-over-year growth in Q1 2025. This strong commercial performance highlights increasing market acceptance, validates clinical efficacy, and reinforces investor confidence. It further accelerates product pipelines and supports the sustained expansion of the cell and gene therapy ecosystem, which further enhances the market growth.

Table: Revenue Performance of Leading Cell and Gene Therapies, Q1 2024 vs. Q1 2025

Source: Alliance for Regenerative Medicine

Market Drivers

Progressive Reimbursement Expansion and Rising Investments Drives Market

The increasing adoption of progressive reimbursement frameworks for advanced therapy medicinal products (ATMPs) acts as a key driver for the cell and gene therapy market. Consistent reimbursement approvals, particularly in regions such as the UK, are improving patient access to high-cost, transformative therapies. The report from Catapult indicates a steady rise in approved and reimbursed therapies, reflecting strong policy support. These frameworks reduce financial barriers, encourage healthcare providers to adopt innovative treatments, and strengthen manufacturer confidence in commercialization. As reimbursement pathways mature globally, they play a critical role in accelerating therapy uptake and market penetration.

The rising global investments in cell and gene therapy act as a major driver fueling market expansion. Increasing capital inflows into regenerative medicine, including both cell and gene therapies, are accelerating research, clinical development, and commercialization activities. These investments enable advancements in manufacturing technologies, clinical trial expansion, and infrastructure development. As funding continues to grow, it enhances innovation capacity and supports the long-term scalability of advanced therapeutic solutions.

Source: Alliance for Regenerative Medicine and Straits Research Analysis

Market Restraints

Declining Private Funding and High Capital Dependency Restrain Cell and Gene Therapy Market Growth

The decline in global private funding acts as a key restraining factor in the cell and gene therapy market. Reduced venture capital and private equity investments limit the availability of financial resources required for early-stage research and clinical development. According to analysis by Van Lanschot Kempen, decreasing private funding trends are impacting innovation pipelines. This reduction in capital inflows slows down the pace of new therapy development and restricts smaller biotech firms from advancing promising candidates, thereby affecting overall market dynamism.

Source: Van Lanschot Kempen Analysis

The high capital dependency for manufacturing, infrastructure, and commercialization acts as another major restraint in the market. Cell and gene therapies require complex production processes, specialized facilities, and stringent regulatory compliance, leading to significant cost burdens. Limited funding availability further exacerbates these challenges, restricting investments in process optimization, scaling capabilities, and global distribution. This results in delayed product launches and limited accessibility, particularly in cost-sensitive markets, ultimately hindering overall market growth.

Market Opportunities

Rising Dominance of CAR-T Therapies and Manufacturing Expansion Offer Growth Opportunities for Cell and Gene Therapy Market Players

The growing dominance of CAR-T cell therapies acts as a key factor creating significant opportunities in the cell and gene therapy market. According to the American Society of Gene & Cell Therapy, CAR-T therapies accounted for nearly 50% of all genetically modified cell therapies in 2025, highlighting strong clinical and commercial demand. This dominance drives the need for specialized manufacturing infrastructure, logistics, and supply chain optimization. Companies are increasingly investing in CAR-T production capabilities to meet rising demand, creating new avenues for technological innovation and scalability.

Source: American Society of Gene + Cell Therapy

The increasing focus on scaling advanced therapy manufacturing capabilities acts as a major opportunity for market players. As the pipeline of cell and gene therapies expands, there is a growing need for efficient, cost-effective, and scalable production systems. Investments in automation, modular manufacturing units, and decentralized production models are gaining traction. This shift enables faster turnaround times, reduces costs, and improves global accessibility of therapies. Consequently, manufacturers that invest in next-generation bioprocessing technologies are well-positioned to capitalize on the expanding market potential.

Regional Analysis

North America: Market Dominance through Advanced Manufacturing and Strong Policy Support

North America dominated the cell and gene therapy market with a share of around 52.16% in 2025, driven by its advanced manufacturing infrastructure and robust regulatory environment. The region benefits from highly specialized production facilities that ensure quality, scalability, and compliance with the stringent standards required for cell and gene therapies. The strong intellectual property protection frameworks encourage continuous innovation and investment in novel therapeutic approaches, further strengthening regional leadership.

The US leads the North America cell and gene therapy market due to strong payer support and progressive reimbursement frameworks that enhance accessibility to advanced therapies. For instance, in July 2025, according to the US Centers for Medicare & Medicaid Services (CMS), approximately 84% of Medicaid beneficiaries with sickle cell disease participated in the CMS Cell and Gene Therapy (CGT) Access Model. This initiative has significantly improved early access to innovative gene therapies, streamlined reimbursement pathways, and promoted broader adoption of advanced treatments. Furthermore, the presence of leading biotechnology companies, high R&D investments, and a well-established clinical trial ecosystem continues to drive market growth in the country.

Canada contributes steadily to regional growth, supported by strong government funding, academic research excellence, and a collaborative biotech ecosystem. National initiatives and public-private partnerships are fostering advancements in regenerative medicine and gene therapy research. The country’s focus on clinical trials, supported by institutions such as the Centre for Commercialization of Regenerative Medicine (CCRM), strengthens its position in translational research. The favorable regulatory frameworks and increasing investments in biomanufacturing capabilities are enabling Canada to expand its footprint in the cell and gene therapy market.

Asia Pacific: Fastest Growth through Expanding Genomics Infrastructure and Booming Biotechnology Support

Asia Pacific is projected to be the fastest-growing region in the cell and gene therapy market, registering a CAGR of around 25.86% during the forecast period. Growth is driven by increasing investments in genomics infrastructure, expanding clinical research capabilities, and rising demand for advanced treatments targeting rare genetic and hematological disorders. Countries such as Japan, South Korea, and Australia are actively strengthening their clinical translation programs and regulatory pathways to accelerate the commercialization and adoption of cell and gene therapies.

Japan plays a significant role in the regional market, supported by its advanced regulatory framework and early adoption of regenerative medicine. The country has established accelerated approval pathways for cell and gene therapies under its Pharmaceuticals and Medical Devices Act (PMD Act), enabling faster commercialization of innovative treatments. Japan’s strong focus on precision medicine, coupled with substantial government funding and a rapidly aging population, drives demand for advanced therapeutic solutions. Continuous investments in stem cell research and clinical applications further strengthen its leadership in the region.

South Korea is emerging as a key innovator, driven by strong government backing and a rapidly growing biotechnology sector. The country has implemented supportive policies and funding programs to accelerate the development and commercialization of advanced therapies. South Korea’s robust manufacturing capabilities, combined with increasing clinical trial activity and global collaborations, position it as a competitive player in the cell and gene therapy market. The presence of leading biotech firms and advancements in CAR-T cell therapy development further contribute to its growth trajectory.

India is emerging as a key growth hub within the region, supported by the development of cost-effective, domestically produced therapies and growing research collaborations. A significant milestone was achieved when India launched its first home-grown CAR-T cell therapy, NexCAR19, developed through a collaboration between IIT Bombay, Tata Memorial Centre, and ImmunoACT. This breakthrough highlights India’s growing capabilities in advanced therapeutics and positions the country as an important contributor to innovation in the global cell and gene therapy landscape. The increasing government support, expanding biotech startups, and improving healthcare infrastructure are further accelerating market growth in the country.

By Therapy Type

The cell therapy segment is expected to register a CAGR of 25.13% during the forecast period, owing to the increasing number of clinical trials that play an essential role in the growth of the market due to their essential role in validating the safety, efficacy and therapeutic potential of new treatments. The table below depicts the data of clinical trials of cell therapy from 2024 to Q1 2025.

Source: Alliance for Regenerative Medicine

The gene therapy segment is anticipated to grow at a CAGR of 25.03% during the forecast period, owing to the rapid transformations in gene editing technologies. Technologies such as CRISPR-Cas9 and TALENs enable highly precise and targeted modifications of the genome, allowing researchers to correct or replace defective genes responsible for a variety of genetic disorders.

By Application

The oncology segment dominated the market with a revenue share of 60.21% in 2025, supporting the growing use of tumor-specific biomarkers to guide personalized treatments. These biomarkers support doctors in identifying exactly which therapy is most likely to work for a patient’s unique cancer type. This targeted approach improves treatment success and reduces side effects, making therapies more appealing and essential in real-world cancer care.

The dermatology segment is expected to register a CAGR of 24.06% during the forecast period, owing to the rising prevalence of rare and chronic skin disorders such as epidermolysis bullosa and vitiligo, which are increasingly being targeted through gene correction and cell regeneration therapies. Growing clinical success of ex vivo gene-edited skin grafts and autologous fibroblast-based treatments has further accelerated adoption.

By Manufacturer

The biopharmaceutical and biotechnology companies segment dominated the market in 2025, with a revenue share of 41.73%. This growth is attributed to the strategic collaborations with academic institutions as well as healthcare facilities, which enable rapid translation of research into commercially viable therapies. Such partnerships facilitate access to specialized expertise and laboratory infrastructure that further accelerate the development, testing, and approval of advanced cell and gene therapies.

The CDMOs/CMOs segment is expected to register a CAGR of 25.54% during the forecast period due to the rising demand for specialized, large-scale manufacturing of cell and gene therapies; increasing outsourcing by biopharmaceutical companies to reduce capital expenditure; and the expansion of GDMP-compliant facilities to support complex therapy production and commercialization.